Skip to main content

Table 1 Baseline clinical characteristics of participants; control & intervention

From: A randomized control trial of primary care-based management of type 2 diabetes by a pharmacist in Pakistan

Clinical Characteristics of Participants in Two Study Arms (At Baseline) [Mean ± SD]
Parameters Control Arm, n = 121 Intervention Arm, n = 123 p–values
Age (Yrs) 50.4 ± 7.7 50.3 ± 10.5 0.89
Age at diagnosis of DM(Yrs) 42.8 ± 7.9 44.2 ± 9.8 0.24
Duration of DM (Yrs) 7.6 ± 5.4 6.1 ± 5.3 0.029*
Haemoglobin (mg/dL) 13.2 4 ± 1.1 13.9 ± 1.1 0.69
Weight (Kg) 78.3 ± 14.4 77.5 ± 17.6 0.72
Waist (cm) 110 ± 16.5 109 ± 16.5 0.86
BMI (Kg/m 2 ) 30.6 ± 4.9 30.8 ± 6.4 0.79
Systolic BP (mmHg) 133 ± 15.4 145 ± 20.9 0.0001**
Diastolic BP (mmHg) 85 ± 10.4 94 ± 10.7 0.0001**
eABG (mg/dL) 261 ± 49.8 268 ± 50.2 0.25
HbA1c 10.7 ± 1.7 11.0 ± 1.7 0.25
Cholesterol (mg/dL) 231 ± 55.7 223 ± 51.3 0.26
Triglycerides(mg/dL) 191 ± 79.7 272 ± 112.1 0.0001**
HDL-C (mg/dL) 48 ± 12.5 49 ± 18.2 0.45
LDL-C (mg/dL) 145 ± 48.5 119 ± 50.3 0.0001**
VLDL-C (mg/dL) 38 ± 15.9 54 ± 22.4 0.0001**
Serum Creatinine (mg/dL) 1.0 ± 0.3 1.1 ± 0.4 0.007*
Treatments
None 2 (1.7%) 1 (0.8%)  
OHA 66 (54.5%) 72 (58.5%) 0.51
OHA + Insulin 43 (35.5%) 45 (36.6%)
Insulin 10 (8.3%) 5 (4.1%)
  1. Abbreviation: SD Standard Deviation, DM Diabetes Mellitus, BMI Body Mass Index, eABG Estimated Average Blood Glucose, HbA1c Glycosylated Haemoglobin, HDL-C High Density Lipoprotein-Cholesterol, LDL-C Low Density Lipoprotein-Cholesterol, VLDL-C Very Low Density Lipoprotein-Cholesterol, OHA Oral Hypoglycaemic Agents, I Intervention, C Control, M Male, F Female
  2. p-values; *p < 0.05–0.002, **p < 0.002–0.0001